Brief: AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD
18/01/2024 23:12
Jan 18 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA PRESENTS POSITIVE CLINICAL AND PRE-CLINICAL
DATA
FOR ABP-450 (PRABOTULINUMTOXINA) IN TREATING CERVICAL DYSTONIA
AND PTSD, RESPECTIVELY, AT A LEADING NEUROTOXIN CONFERENCE
* AEON - OPEN LABEL EXTENSION PHASE 2 DATA SHOW PEAK
EFFICACY FOR
ALL ABP-450 DOSES AND CYCLES IN TREATING CERVICAL DYSTONIA
OCCURRED EARLY
Source text for Eikon: ID:nGNXc2PNqY
Further company coverage: AEON.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition